From immuno-oncology to precision diagnostics, Korean biotech innovators are scaling beyond Asia.
Korea’s biotech industry is evolving rapidly—backed by strong government support, a skilled talent pool, and increasing global investment. In 2025, a wave of Korean biotech startups is making serious moves into global pharma, diagnostics, and therapeutics markets. Some are licensing out novel molecules to Big Pharma, others are seeking FDA approvals, and many are at the cutting edge of precision medicine.
Here are five biotech startups from Korea that are poised to make an international impact.
1. ABL Bio – Bispecific Antibodies for Cancer & Neurology
- Focus: Immuno-oncology and neurodegenerative disease treatment using bispecific antibodies.
- Notable Deal: $1.06 billion licensing deal with Sanofi for Parkinson’s-targeted molecule.
- Global edge: ABL Bio’s “Grabody” platform is being used to cross the blood-brain barrier (BBB), a known hurdle in CNS drug delivery.
- Why it matters: Its pipeline includes both first-in-class and best-in-class candidates targeting Alzheimer’s, Parkinson’s, and solid tumors.
2. Geninus – Precision Genomics and Cancer Diagnostics
- What they do: A spin-off from Seoul National University Hospital, Geninus offers next-generation sequencing (NGS) services and proprietary AI analytics for cancer and rare disease diagnostics.
- Strength: Their platform leverages Korean clinical genomic databases, giving them an edge in ethnically relevant biomarkers.
- Global status: Actively participating in international research consortia and pursuing FDA-level clinical validation.
- Why it matters: Geninus is bringing population-specific precision medicine to an international stage.
3. Mediwhale – Predictive Health via Retinal Imaging
- Innovation: Non-invasive cardiovascular and kidney disease prediction using retina scans and AI.
- Clinical footprint: Deployed in hospitals across Asia and Europe; pursuing U.S. partnerships.
- Why it matters: In a world shifting to preventive medicine, Mediwhale’s 30-second eye scan could change how we screen at-risk populations.
4. Aprinoia Therapeutics Korea – Neuroimaging Biomarkers
- What they do: Develops PET imaging agents for Alzheimer’s and tauopathies, enabling early diagnosis and monitoring of neurodegenerative diseases.
- Global reach: Clinical trials in the U.S. and partnerships with imaging centers worldwide.
- Why it matters: As Alzheimer’s diagnostics become mainstream, Aprinoia’s tau tracers could offer more specific and sensitive tools than amyloid-based agents.
5. GI Innovation – Immunotherapy and Metabolic Disease Biologics
- Pipeline: Dual-action fusion proteins targeting IL-2 and TGF-β pathways, with applications in both oncology and autoimmune disorders.
- Milestone: Signed a $900M+ deal with Simcere (China) and progressing into U.S. trials.
- Why it matters: GI Innovation is one of Korea’s most clinically advanced biotech startups, showing how Korean R&D can scale globally.
🌍 Why Korean Biotech Is Worth Watching Globally
- Strong clinical infrastructure and health data systems
- Robust IP strategy and out-licensing capability
- Rising track record of large licensing deals with global pharma
- Strategic focus on immunotherapy, neurology, and AI-integrated diagnostics
With a unique mix of research depth and global ambition, these Korean startups are not just competing—they’re redefining what biotech leadership looks like in Asia.